Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
Chuangxing Guo(Pfizer (United States)), Andrea Fanjul(Pfizer (United States)), Paul Richardson(Pfizer (United States)), David M. Briere(Mirati Therapeutics (United States)), Kevin N. Dack(Pfizer (United States)), Martha A. Ornelas(Pfizer (United States)), Natilie Hosea(University of British Columbia), Andrew Morell(Pfizer (United Kingdom)), Toby J. Underwood(Pfizer (United Kingdom)), Robert Felstead(Pfizer (United Kingdom)), Hidetoshi Kuruma(Tomitahama Hospital), S.E. Greasley(University of British Columbia), Susan E. Kephart(Pfizer (United States)), Martin P. Edwards(Pfizer (United States)), Angelica Linton(University of British Columbia), Martin Gleave(University of British Columbia), Ping Kang(University of British Columbia), Hovik Gukasyan(University of British Columbia), Asako Nagata(Pfizer (United States)), Jon Engebretsen(Pfizer (United States)), Wenyue Hu(Beijing University of Chinese Medicine), Amina Zoubeidi(Cervantes Institute), Patrick S. Johnson(Pfizer (United States)), Gerrit Los(Pfizer (United States)), Mason Pairish(Pfizer (United States)), Javier González(National Cancer Institute), Manli Shi(Pfizer (United States)), Hiroaki Matsimoto(University of British Columbia), Benjamin J. Burke(Pfizer (United States))
Cited by 69
Related Papers
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Antisense therapy for cancer
|Nature reviews. Cancer|2005|399